These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17475604)

  • 1. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
    Chang HH; Yang YL; Hung MH; Tsay W; Shen MC
    J Formos Med Assoc; 2007 Apr; 106(4):281-7. PubMed ID: 17475604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
    Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
    Alamelu J; Bevan D; Sorensen B; Rangarajan S
    J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
    Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
    J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful management of neurosurgical procedures with continuous infusion of recombinant factor IX in a child with hemophilia B].
    Yamamoto M; Nakadate H; Iguchi U; Masuda H; Sakai H; Ishiguro A
    Rinsho Ketsueki; 2013 Mar; 54(3):300-4. PubMed ID: 23676647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
    Shapiro AD; Di Paola J; Cohen A; Pasi KJ; Heisel MA; Blanchette VS; Abshire TC; Hoots WK; Lusher JM; Negrier C; Rothschild C; Roth DA
    Blood; 2005 Jan; 105(2):518-25. PubMed ID: 15383463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
    Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S
    Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
    Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
    J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
    Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
    Björkman S
    Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
    McCarthy K; Stewart P; Sigman J; Read M; Keith JC; Brinkhous KM; Nichols TC; Schaub RG
    Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
    Björkman S
    Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.